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ABSTRACT 
 
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase 
receptor that, upon activation, triggers several pathways, such as the RAS/RAF/ERK 
pathway, that are often deregulated in colorectal carcinomas.  Two monoclonal antibodies 
targeting EGFR, cetuximab and panitumumab, have proven to be effective in the 
treatment of metastatic colorectal cancer (mCRC). However, it was discovered that 
patients with activating mutations in exon 2 (codons 12/13) of the KRAS gene do not 
respond to this therapy, establishing them as the first negative predictors of response to 
anti-EGFR therapy.  
The KRAS gene, an effector of EGFR signaling through the RAS/RAF/ERK pathway, is 
mutated in exon 2 in about 40% of all mCRC. In KRAS exon 2 wild-type patients, only 40 
to 60% achieve a response when receiving this therapy, something that suggests that 
alterations in other EGFR downstream effectors may also be associated with the lack of 
response to this therapy. Recently, the importance of less frequent KRAS and NRAS 
(RAS) mutations has been uncovered based on new results from recent clinical trials, 
which reported that patients with rarer activating RAS mutations also do not benefit from 
anti-EGFR therapy. This information shows the need to identify new predictive biomarkers 
that might help to select patients who are most likely to benefit from anti-EGFR.   
In a consecutive series of 241 mCRC samples, wild-type for KRAS codons 12 and 13, 
we searched for less frequent RAS mutations that might act as predictor of response to 
anti-EGFR therapy, namely mutations in less frequent mutational hotspots in KRAS (exon 
3 and 4) and NRAS (exons 2, 3 and 4).  
About 19% (46/241) of the cases evaluated had a mutation in the analyzed regions. All 
mutations were found in heteregozity and were mutually exclusive. Thirty cases (12.4%; 
30/241) had a KRAS mutation and sixteen (6.6%; 16/241) had a NRAS mutation, with the 
following distribution: thirteen mutations were found in KRAS exon 3 (28.3%; 13/46), 
seventeen in KRAS exon 4 (37.0%; 17/46), eight in NRAS exon 2 (17.4%; 8/46) and eight 
in NRAS exon 3 (17.4%; 8/46). No mutations were found in exon 4 of the NRAS gene. 
One novel point mutation, not previously described in CRC, was found in exon 3 of the 
NRAS gene in two cases. KRAS mutations were more frequent in earlier than in later 
stages at diagnosis (P=0.001). 
In conclusion, nearly one-fifth of mCRC patients wild-type for KRAS exon 2 (codons 
12/13) present other, less frequent, RAS mutations that might be associated with lack of 
response to anti-EGFR therapy. However, further studies are necessary to confirm these 
mutations as negative predictors of response to this therapy in the patients of our series.
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RESUMO 
 
O recetor de fator de crescimento epidérmico (EGFR) é uma tirosina cinase 
transmembranar que, após ativação, inicia diversas vias de transdução de sinal, tais 
como a via RAS/RAF/ERK, cuja atividade está frequentemente desregulada em 
carcinomas colo-retais. Dois anticorpos monoclonais dirigidos ao EGFR, cetuximab e 
panitumumab, provaram ser eficazes no tratamento do cancro colo-retal metastático. No 
entanto, foi descoberto que indivíduos com mutações ativantes nos codões 12 e 13 do 
gene KRAS não beneficiam deste tratamento, o que as torna no primeiro biomarcador 
preditivo de ausência de resposta à terapia anti-EGFR. 
O gene KRAS, um efetor do EGFR através da via de transdução de sinal 
RAS/RAF/ERK, está mutado no exão 2 em cerca de 40% dos carcinomas colo-retais 
metastáticos. Dos doentes sem mutação no exão 2 do KRAS, só 40 a 60% respondem ao 
tratamento, o que sugere que alterações noutras proteínas efetoras do EGFR poderão 
estar envolvidas nesta ausência de resposta. Recentemente, foi revelada a importância 
de mutações menos frequentes nos genes KRAS e NRAS (RAS) em ensaios clínicos, 
que reportaram que indivíduos com estas mutações não beneficiam do tratamento com 
anti-EGFR. 
Numa série consecutiva de 241 casos de carcinoma colo-retal metastático, sem 
mutações nos codões 12 e 13 do KRAS, procurámos mutações RAS menos frequentes 
que possam ser usadas como biomarcadores preditivos de resposta à terapia com 
cetuximab e panitumumab. Em particular, foram pesquisadas mutações noutros codões 
do KRAS (exões 3 e 4) e do NRAS (exões 2, 3 e 4). 
Cerca de 19% (46/241) dos casos analisados apresentavam uma mutação nas regiões 
analisadas. Todas as mutações foram encontradas em heterozigotia e eram mutuamente 
exclusivas. Trinta casos (12,4%; 30/241) tinham uma mutação no KRAS e dezasseis 
(6,6%; 16/241) no NRAS, com a seguinte distribuição: treze mutações no exão 3 (28,3%; 
13/46) e dezassete no exão 4 (37,0%; 17/46) do KRAS; oito no exão 2 (17,4%; 8/46) e 
oito no exão 3 (17,4%; 8/46) do NRAS. Não foram encontradas mutações no exão 4 do 
gene NRAS. Uma mutação pontual nova, não descrita em cancro colo-retal, foi 
encontrada no exão 3 do NRAS em dois casos. As mutações no KRAS foram mais 
frequentes nos estádios mais precoces do que nos mais tardios na altura do diagnóstico 
(p=0,001). 
Em conclusão, aproximadamente um quinto dos doentes com cancro colo-retal 
metastático, sem mutações nos codões 12 e 13 do KRAS, apresentam outras mutações 
RAS menos frequentes que podem estar associadas à ausência de resposta à terapia 
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anti-EGFR. No entanto, são necessários estudos adicionais para confirmar o papel 
destas mutações como biomarcadores preditivos de ausência de resposta a esta terapia 
nos doentes da nossa série. 
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I. INTRODUCTION 
 
 
 
With over 14 million new cancer cases and 8.2 million cancer deaths estimated to have 
occurred in 2012 (IARC, 2013), cancer is among the leading causes of death in the world. 
The burden of this malignancy seems to be increasing in economic developing countries, 
mostly due to population aging and growth, as well as a result of an increasing adoption of 
cancer-associated behaviors, such as smoking (Jemal et al., 2011). Despite increasing 
awareness, colorectal cancer (CRC) remains as one of the most common cancers 
worldwide. 
 
Epidemiology 
CRC is a major cause of morbidity and mortality throughout the world, with over 1.3 
million new cases diagnosed in 2012 (Figure 1). Europe and North America are among 
the regions with the highest incidence rates for this type of cancer. This rate is rapidly 
increasing in several areas that are considered as low risk areas, such as Eastern Asia. 
This might be the reflection of changes in dietary and lifestyle factors associated with 
“westernization”, like smoking or obesity. In contrast to these high incidence trends, the 
occurrence of this pathology seems to be decreasing in several parts of the world, 
including the United States, probably due to population screening schemes that allow 
early detection of CRC and removal of precancerous lesions (Jemal et al., 2011; Ferlay et 
al., 2013; IARC, 2013). 
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In 2012, CRC was the second most common malignancy in Europe (excluding non-
melanoma skin cancers), with 464.000 newly diagnosed cases estimated to have 
occurred, which accounts for 12.1% of all cancer cases. It had the third highest incidence 
in men, following prostate and lung cancer, and the second in women, only surpassed by 
breast cancer. This malignancy is slightly more incident in men than in women.  It was 
also the second most frequent cause of death by cancer, with almost 215 000 deaths 
estimated, which accounts for 12.2% of all cancer deaths (Ferlay et al., 2013). 
In terms of CRC incidence and mortality, Portugal follows the same patterns of Europe 
(Figure 2). In 2012, it was the highest incident malignancy, with 7129 new cases 
diagnosed. Data analysis by sex demonstrated that CRC has the second highest 
incidence in both sexes, after prostate (male) and breast cancer (female). It was also the 
leading cause of death by cancer, with 3797 deaths, which accounts for 15.7% of all 
cancer deaths (Ferlay et al., 2013; IARC, 2013). 
 
 
Figure 1. Estimated age-standardised incidence and mortality rates of 
CRC for male and female, in the world [Globocan, 2012 (IARC, 2013)].  
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Risk Factors 
CRC is a very complex and heterogeneous disease and several etiologic factors 
contribute to the appearance of this malignancy.  
The risk of developing CRC increases with age, preferentially after the age of 40. It is 
estimated that more than 90% of the patients diagnosed with this malignancy are aged 50 
or older (Amersi et al., 2005; Haggar & Boushey, 2009). 
CRC usually occurs in one of three patterns: inherited, familial or sporadic. Inherited 
forms are responsible for about 5-10% of all CRC cancers, and are related to recognized 
hereditary conditions (Figure 3). The most common are familial adenomatous polyposis 
(FAP) and hereditary nonpolyposis colorectal cancer  (HNPCC), also know as Lynch 
syndrome, which are responsible for 1% and 2%-4% of all CRC cases, respectively 
(Amersi et al., 2005; Rustgi, 2007; Haggar & Boushey, 2009; Jasperson et al., 2010). 
Other inherited diseases that lead to an increased risk of CRC are MUYTH-associated 
polyposis (MAP), Peutz-Jeghers syndrome (PJS) and juvenile polyposis syndrome (JPS) 
(Rustgi, 2007; Jasperson et al., 2010). 
Familial cases are defined as families with increased predisposition to cancer, probably 
due to an hereditary basis with the involvement of genes that are less penetrant and/or 
the sign of shared environmental and lifestyle factors. It is estimated that about 20-30% of 
all CRC cases occur in this context (Rustgi, 2007; Jasperson et al., 2010). 
A B 
Figure 2. Estimated age-standardised incidence and mortality rates of CRC for male and female, in A) 
Europe and B) Portugal [Globocan, 2012 (IARC, 2013)].   
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Although genetics, family history and susceptibility factors play an important role in 
the development of this disease, the majority of CRCs are sporadic (~70%), with no prior 
family history (Haggar & Boushey, 2009). Several epidemiological studies have confirmed 
the influence of numerous environmental and dietary factors in the etiology of this 
disease, such as a diet high in fat and low in fiber, a sedentary lifestyle, obesity, diabetes, 
cigarette smoking and alcohol abuse (Haggar & Boushey, 2009; Chan & Giovannucci, 
2010; Gingras & Beliveau, 2011; Colussi et al., 2013). Physical activity, on the other hand, 
is thought to lower CRC risk. In fact, several studies report that higher overall levels of 
physical activity are associated with a decreased risk of CRC of ~20% (Huxley et al., 
2009). Another risk factor is the presence of chronic inflammatory bowel diseases (IBD), 
such as Crohn’s disease or ulcerative colitis (Ilyas et al., 1999; Colussi et al., 2013). 
 
CRC Diagnosis and Staging 
CRC diagnosis is usually made after the onset of the symptomatology of the disease, 
but most of the symptoms (rectal bleeding, blood in the stools, change in bowel habits) 
are non-specific and consistent with other conditions besides CRC. This, along with the 
fact that most patients with an early-stage disease are asymptomatic, presents difficulties 
when trying to diagnose this disease. The most common screening techniques are the 
fecal occult blood test and/or colonoscopy, the latter allowing direct inspection of the 
entire colon and same-session biopsy necessary for histopathological diagnosis. Patients 
should also undergo a physical examination and may perform computed tomography 
(CT), magnetic resonance imaging (MRI) or fluorodeoxyglucose-positron emission 
Figure 3. Circle graph depicting the genotypic and phenotypic heterogeneity in CRC 
[adapted from (Lynch et al., 2009)].    
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tomography (FDG-PET), which allow the identification and characterization of a possible 
metastatic disease (Levin et al., 2008; Van Cutsem, Nordlinger, et al., 2010; Cummings & 
Cooper, 2011). 
Once diagnosis is made, it is necessary to stage the tumor according to its pathological 
characteristics. Staging assessment is a key factor used to define treatment and to 
estimate the chance of a successful treatment outcome. The most common staging 
system for CRC is the TNM system (Centelles, 2012). Each of the three letters of the TNM 
system (Table 1), according to the American Joint Committee on Cancer (AJCC), stand 
for a specific meaning in regard to the characteristics of the tumor: T - size and/or extent 
(reach) of the primary tumor; N - amount of spread to nearby lymph nodes; and M - 
presence of metastasis or secondary tumors caused by the spread of cancer cells to other 
parts of the body (Edge et al., 2010; Centelles, 2012). It is also important to report the 
timing of the staging assessment. Clinical staging – or cTNM – includes any information 
obtained before initiation of any kind of preoperative treatment. Pathological staging – 
pTNM – is defined by the information obtained after the examination of the surgically 
removed tissues (Edge et al., 2010). 
 
Table 1. AJCC cancer stanging for colon and rectal carcinomas [adapted from (Shia et al., 2012)]. 
 Primary Tumor (T) 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral perinoteum 
T4b Tumor directly invades or is adherent to other organs or structures  
 Regional Lymph Nodes (N) 
Nx Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues 
without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
 Distant Metastasis (M) 
M0 No distant metastasis (no pathological M0; use clinical M to complete stage group) 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site (eg. liver, lung, ovary, nonregional node) 
M1b Metastases in more than 1 organ/site or the peritoneum 
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Based on TNM categories, cases with similar prognosis are grouped together in 
staging groups ranging from 0 to IV, with number IV representing the group with worse 
prognosis (Table 2). 
 
Table 2. Staging groups for CRC, according to AJCC guidelines [adapted from (Centelles, 2012)]. 
  T N M 
Stage 0  Tis N0 M0 
Stage I  T1-T2 N0 M0 
Stage IIA  T3 N0 M0 
Stage IIB  T4a N0 M0 
Stage IIC  T4b N0 M0 
Stage IIIA 
 T1-T2 
T1 
N1 
N2a 
M0 
M0 
Stage IIIB 
 T3-T4 
T2-T3 
T1-T2 
N1 
N2a 
N2b 
M0 
M0 
M0 
Stage IIIC 
 T4a 
T3-T4 
T4b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
Stage IV 
 Any T 
Any T 
Any N 
Any N 
M1a 
M1b 
 
CRC treatment 
 Among the different approaches used for the treatment of CRC, surgery is still the 
most common one, due to its curative intent. The goal of surgery is the complete resection 
of the tumor, which has a greater chance of success in localized diseases. After the 
resection, adjuvant therapy is recommended for stage III and “high-risk” stage II patients 
(Labianca et al., 2010; Hagan et al., 2013). However, about 20 to 25% of patients present 
metastatic disease at the time of the diagnosis, and 40 to 50% of newly diagnosed 
patients develop metastases over the course of the disease (Van Cutsem et al., 2009). 
The majority of patients with metastatic colorectal cancer (mCRC) are not suitable for 
resection. However, in a small portion of cases, surgical resection can be achieved after 
the downsizing of the metastases with the administration of systemic therapy. On the 
other hand, patients with unresectable mCRC are subjected to systemic therapy with a 
palliative intent, rather than a curative one (Van Cutsem, Nordlinger, et al., 2010; Edwards 
et al., 2012).  
 Over the years, the standard chemotherapeutic (CT) regimens available evolved with 
the addition of several new therapeutic agents. For almost 40 years, 5-Fluorouracil (5-FU) 
was the only effective chemotherapeutic option for mCRC and nowadays it still remains a 
mainstay in mCRC treatment, in combination with other agents. This uracil analogue is 
converted into active metabolites, which inhibit the enzyme thymidylate synthase (TS). 
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This enzyme mediates the conversion of deoxyuridine monophosphate (dUMP) to 
deoxynucleotide triphosphates (dTMP), used in DNA synthesis. Its inhibition by 5-FU 
administration is then responsible for diminishing the availability of dTMPs, causing 
disruption of DNA synthesis and repair, which lead to cell death. 5-FU is usually 
administered with leucovorin (LV), a modulator that stabilizes the 5-FU-TS complex, 
increasing 5-FU cytotoxicity (Noordhuis et al., 2004; Hirsch & Zafar, 2011). Due to the 
significant variation of its bioavailability when given orally, 5-FU can only be delivered in 
bolus or continuous infusion. This drawback led to the design of a prodrug (capecitabine) 
that can be administered orally and is equivalent to a continuous 5-FU infusion in terms of 
efficacy and overall survival of patients (Cassidy et al., 2011; Hirsch & Zafar, 2011).  
Besides 5-FU, two other agents – irinotecan and oxaliplatin – are currently used in 
standard combination CT regimens, which provide higher response rates and longer 
progression free survival, when compared with their administration as single agents (Van 
Cutsem, Nordlinger, et al., 2010; Edwards et al., 2012).  Irinotecan is responsible for the 
inhibition of topoisomerase I, which causes irreversible single strand DNA breaks that lead 
to cell death. Oxaliplatin is a third generation platinum-based drug that acts by forming 
DNA adducts capable of restraining DNA replication and transcription. These agents may 
be administered in several combination regimens, such as FOLFOX (5-FU/LV/oxaliplatin), 
FOLFIRI (5-FU/LV/irinotecan) and CAPOX (capecitabine/oxaliplatin) (Lentz et al., 2005; 
Van Cutsem, Nordlinger, et al., 2010; Edwards et al., 2012; NCCN, 2013). 
Recent advances in the knowledge of the molecular pathology of tumors have led to 
the development of molecular targeted therapies, designed to interfere with specific 
molecules involved in carcinogenesis. In mCRC treatment, two molecules are targets of 
this kind of therapy: vascular endothelial growth factor (VEGF) and epidermal growth 
factor receptor (EGFR), with the former being targeted by bevacizumab and the latter by 
cetuximab and panitumumab. The introduction of these drugs in the treatment of mCRC 
patients resulted in a considerable improvement of median progression free survival 
(PFS) and response rates (RR) (Van Cutsem, Nordlinger, et al., 2010; Edwards et al., 
2012). 
Neoangiogenesis has been recognized for decades as a fundamental event in tumor 
growth and metastatic dissemination and the VEGF pathway is appointed as one of the 
major pathways involved in this process (Hicklin & Ellis, 2005; El Zouhairi et al., 2011). 
VEGF is a proangiogenic factor overexpressed in several types of cancer, including CRC. 
It acts by binding to VEGF receptor (VEGFR) and triggering a cascade of different 
signaling pathways, such as proliferation and migration of endothelial cells and promotion 
of increased vascular permeability (Hicklin & Ellis, 2005; Kerbel, 2008).  Bevacizumab is a 
recombinant humanized monoclonal antibody (moAb) that binds to VEGF and prevents it 
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from interacting with the receptors, thus inhibiting angiogenesis and altering vascular 
function and tumor blood flow. Bevacizumab as a single agent induces minimal response 
rates, however its true benefit lies in the combination with the traditional chemotherapy 
agents, since it normalizes the tumor vasculature, improving the delivery of anticancer 
agents to tumors (Ellis, 2006). It is now used as first-line treatment for mCRC, in 
combination with fluoropyrimidine-based CT regimens (Van Cutsem, Nordlinger, et al., 
2010; Edwards et al., 2012; NCCN, 2013). 
EGFR is a transmembrane receptor tyrosine kinase (TK) and a member of the ErbB 
family of receptor TKs whose abnormal activation is associated with uncontrolled cell 
proliferation, among other effects. EGFR is overexpressed on the surface of several 
epithelial tumors, including CRC (25 to 80% of cases) (Marshall, 2006). Cetuximab, a 
chimeric monoclonal IgG1, and panitumumab, a fully human IgG2, compete with EGFR’s 
ligands and bind to the receptor, inhibiting activation of the downstream cell signaling 
pathways (Marshall, 2006; Ciardiello & Tortora, 2008). Both agents have been evaluated 
in several clinical trials, which resulted in their approval by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMEA). At that time, it was 
also established as a guideline that all patients should be screened for KRAS mutations in 
codons 12 and 13 before anti-EGFR treatment, since these mutations were recognized as 
negative predictors of response to anti-EGFR therapy in CRC.  Both moAbs are indicated 
for the treatment of mCRC KRAS wild-type in combination with fluoropyrimidine-, 
oxaliplatin- and irinotecan-containing CT regimens (Schmoll et al., 2012; NCCN, 2013). 
 
Colorectal carcinogenesis 
The development of targeted therapies, which revolutionized mCRC treatment, was 
possible due to the growing understanding of the molecular mechanisms driving colorectal 
carcinogenesis. CRC evolves through a stepwise accumulation of several genetic and 
epigenetic alterations, which lead to the transformation of normal colonic mucosa into an 
invasive lesion. However, the identification of different molecular pathways of colorectal 
carcinogenesis has revealed the heterogeneity of this disease. 
In 1990, Fearon and Vogelstein proposed the first genetic colorectal carcinogenesis 
model, the adenoma-carcinoma sequence model, which demonstrated the heterogeneous 
nature of CRC. This model was based upon four different features: 1) Tumor arising 
depends on the activation of oncogenes coupled with the inactivation of tumor suppressor 
genes; 2) Mutations in at least four to five genes are required for malignant transformation 
(fewer changes lead to benign lesions; 3) When determining the tumor’s biologic 
characteristics, total accumulation of changes is more important than the order in which 
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they occur; 4) In some cases, mutant suppressor genes seem to exert a phenotypic effect, 
even in the heterozygous state, possibly meaning that not all tumor suppressor genes are 
“recessive” at the cellular level, like the TP53 gene (Fearon & Vogelstein, 1990).   
According to this model, the inactivation of the APC gene is described as the initiating 
event of colorectal carcinogenesis, leading to the formation of adenomas from normal 
colonical epithelium. Subsequent evolution of adenomas is frequently associated with 
activating mutations in KRAS, followed by allelic loss of chromosome 18q and inactivation 
of genes such as DCC or SMAD2/4 (involved in the TGF-β pathway). Other genetic 
alterations, such as loss of heterozygosity (LOH) of chromosome 17p and inactivation of 
TP53 gene, mediate the progression from adenoma to carcinoma (Figure 4) (Fearon & 
Vogelstein, 1990; Ilyas et al., 1999; Worthley et al., 2007; Al-Sohaily et al., 2012; Kanthan 
et al., 2012). However, it is thought that only about 60% of the CRC cases follow the 
sequence highlighted by this model. This evidence suggests that other molecular 
modifications and/or pathways might be implicated in CRC carcinogenesis, and may lead 
to a more complete and refined model. 
 Currently, colorectal carcinogenesis is viewed as a result of the “genomic instability” 
phenomena, which denotes the loss of mechanisms involved in the maintenance of 
genomic fidelity and apoptosis that lead to the accumulation of alterations associated with 
colorectal tumorigenesis. Based on this theory, three distinct pathways were 
characterized: Chromosomal instability (CIN), microsatellite instability (MSI) and CpG 
island methylator phenotype (CIMP) (Worthley et al., 2007; Al-Sohaily et al., 2012; 
Kanthan et al., 2012). 
 
 
  
Figure 4. Different steps of the adenoma-carcinoma sequence and the alterations associated with each 
one [adapted from (Moran et al., 2010)]. 
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Chromosomal instability (CIN) pathway  
The CIN pathway, also known as “suppressor” or “traditional” pathway, is the most 
common cause of genomic instability in CRC, encompassing 70-85% of all the sporadic 
CRC cases. It is characterized by the accumulation of numerical or structural 
chromosomal abnormalities that involve regions harboring genes crucial for the process of 
colorectal carcinogenesis (Worthley et al., 2007; Markowitz & Bertagnolli, 2009; Al-Sohaily 
et al., 2012; Kanthan et al., 2012). Frequent LOH at tumor suppressor gene loci and 
chromosomal rearrangements are characteristics of this type of tumors (Bogaert & 
Prenen, 2014). Alterations to the CIN pathway result from anomalies in chromosome 
segregation, with subsequent telomerase dysfunction/overexpression and defects in the 
DNA damage response mechanisms (Al-Sohaily et al., 2012; Kanthan et al., 2012). The 
majority of the CIN tumors is located in the distal colon and is associated with poor 
prognosis (Kanthan et al., 2012). 
 
The Wnt signaling pathway 
The “key” mutational event of this pathway occurs in the APC tumor suppressor gene. 
It is described as a “gatekeeper” gene of cellular proliferation in CRC that is associated 
with both sporadic CIN and, when mutated in the germline, the FAP syndrome (Ilyas et al., 
1999; Worthley et al., 2007; Al-Sohaily et al., 2012; Colussi et al., 2013). This gene is 
involved in the Wnt signaling pathway and it is an important component of a degradation 
complex responsible for regulating β-catenin levels (Figure 5). APC inactivation impairs 
the normal degradation of β-catenin, leading to its cytoplasmic accumulation and eventual 
translocation into the nucleus, where it acts as a transcriptional co-activator of the TCF 
transcription factors family, affecting important cellular mechanisms, such as proliferation, 
differentiation and migration of normal cells (Worthley et al., 2007; Al-Sohaily et al., 2012; 
Colussi et al., 2013). Cyclin D1 (CCND1) is one of the genes affected by this abnormal 
activation of the Wnt pathway. Increased CCND1 regulation contributes to the 
development of this neoplasia by allowing the cell to evade apoptosis (Colussi et al., 
2013).  
Other genetic alterations involved in β-catenin regulation include gain-of-function 
mutations in the β-catenin gene (CTNNB1), present in up to 50% of tumors lacking an 
APC mutation (Pino & Chung, 2010; Kanthan et al., 2012; Colussi et al., 2013) or CDK8 
gene amplification (Colussi et al., 2013). 
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RAS pathway  
KRAS gene mutations are one of the subsequent events to the early mutations above 
mentioned that lead to the progression from benign to malignant stages (Colussi et al., 
2013). KRAS is a proto-oncogene that encodes a GTP-binding protein, which is involved 
in the transduction and propagation of external signals. Somatic mutations in this gene, 
especially at exon 2, can cause a loss of inherent GTPase activity. This loss constitutively 
activates the mitogen-activated protein kinase (MAPK) signaling pathway, responsible for 
controlling cellular growth, survival, apoptosis, cell motility, differentiation and proliferation. 
This active state allows the cell to evade apoptosis and acquire a growth advantage (Ilyas 
et al., 1999; Worthley et al., 2007; Al-Sohaily et al., 2012; Colussi et al., 2013).  
 
TP53 
Alterations in the p53 tumor suppressor protein and its respective gene (TP53), 
localized in chromosome 17p, are common in most human cancers. In normal cells, the 
p53 protein, often designated as the “guardian” of the genome, is responsible for: 1) 
repairing DNA when a persistent damage occurs; 2) arresting cell cycle at the G1/S 
regulation point of DNA damage recognition; and 3) initiating apoptosis by inducing pro-
apoptotic genes when DNA damage is irreparable (Worthley et al., 2007; Kanthan et al., 
2012). Inactivation of TP53 is, thereby, a key step in CRC development and is generally a 
late event in the traditional pathway. This inactivation is usually a combination of a 
missense mutation that inactivates the transcriptional activity of p53 and a 17p 
chromosome deletion of the second TP53 allele (Markowitz & Bertagnolli, 2009; Kanthan 
et al., 2012).  
Figure 5. Wnt pathway in the presence of A) wild-type APC and B) 
mutated APC [adapted from (Pino & Chung, 2010)]. 
A B 
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Other pathways involved in CIN 
SMAD2, SMAD4 and DCC genes are all located in the long arm of chromosome 18 
(18q21.1). SMAD2 and SMAD4 are transcription factors involved in the TGF-β signaling 
pathway that regulates growth as well as apoptosis. The DCC gene codes for a large 
membrane receptor protein, from the immunoglobulin superfamily, that promotes 
apoptosis in the absence of its ligand (netrin-1) (Ilyas et al., 1999; Worthley et al., 2007). 
LOH of 18q is associated with negative prognosis and is reported in up to 60% of CRCs 
(Worthley et al., 2007; Colussi et al., 2013).  
Mutations in the phosphoinositide-3 kinase gene (PIK3CA), detected in approximately 
a third of CRCs, often occur simultaneously with APC mutations, and cause increased 
AKT signaling even without the presence of growth factors. They also interact with a 
central regulator of cell growth and metabolism (mTOR) and with KRAS. Additionally, the 
phosphatase and tensin homolog (PTEN), which acts as a tumor suppressor gene in this 
pathway due to its inhibitory effect on PI3K-AKT signaling, is silenced in nearly 30% of 
CRC (Kanthan et al., 2012; Yu et al., 2014).  
 
Microsatellite instability (MSI) pathway 
Microsatellites are short repeat nucleotide sequences located throughout the genome, 
in both coding and non-coding regions. Because of their repetitive structure, they are 
prone to errors that occur during DNA replication. Those errors are recognized and 
repaired by the DNA Mismatch Repair (MMR) system during replication, which ensures a 
correct DNA synthesis (Al-Sohaily et al., 2012; Kanthan et al., 2012). The MMR system is 
composed of multiple interacting proteins, such as MSH2 and MLH1, and mutations in the 
genes encoding these proteins lead to the inactivation of the MMR system and the 
accumulation of several DNA replication errors, resulting in MSI (Ilyas et al., 1999; 
Markowitz & Bertagnolli, 2009; Al-Sohaily et al., 2012; Kanthan et al., 2012).  
MSI is the hallmark of the HNPCC syndrome, originated by MMR germline mutations. 
This pathway is also involved in the genesis of approximately 15% of sporadic CRC cases 
and is mostly caused by epigenetic silencing of the MLH1 gene promoter (Al-Sohaily et 
al., 2012; Kanthan et al., 2012; Colussi et al., 2013; Bogaert & Prenen, 2014). Tumors that 
develop through this particular pathway present a different phenotype from CIN positive 
CRCs: they are more likely to arise in the proximal colon, are poorly differentiated, often 
exhibit lymphocytic infiltration and, in general, patients affected by MSI-high (MSI-H) 
CRCs present better prognosis and survival. Sporadic MSI-H tumors are also 
characterized by a low frequency of APC, CTNNB1 and KRAS mutations and a high 
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frequency of BRAF mutations, a member of the RAF family involved in the mediation of 
cellular response through the RAS-RAF-ERK pathway. 
Several other genes, such as TGFβRII and BAX, are also mutated in these CRCs. 
TGFβRII inactivating mutations are found in more than 80% of all MSI-H CRCs and are 
involved in the adenoma transition to high-grade dysplasia or metastatic carcinoma. 
Mutations in the SMAD2 and SMAD4 genes, involved in the deactivation of TGFβ 
signaling, are also common in MSI-H CRCs. The pro-apoptotic tumor suppressor gene 
BAX is mutated in 50% of CRCs cases and allows tumor cells to evade the intrinsic 
apoptosis mechanisms. Additionally, mutations in other genes, such as MSH3 and MSH6, 
Insulin Growth Factor Type 2 Receptor (IGFIIR) or CCND1, are also frequently present in 
MSI-H CRCs, although at a lower frequency then the ones mentioned above (Colussi et 
al., 2013).  
 
CpG island methylator phenotype (CIMP)  
This third pathway, present in approximately 20 to 30% of CRC, consists of the 
aberrant hypermethylation of the CpG dinucleotide sequences localized in the promoter 
regions of genes involved in several functions, such as cell cycle regulation, apoptosis, 
DNA repair and invasion. This hypermethylation results in gene silencing, which provides 
an alternative mechanism for loss of function of tumor suppressor genes. In fact, the 
epigenetic silencing of a gene is biologically equivalent to acquiring an inactivating 
mutation, so it can occur as a first, second or both hits to inhibit gene expression 
(Worthley et al., 2007; Markowitz & Bertagnolli, 2009; Al-Sohaily et al., 2012; Colussi et 
al., 2013).  
CIMP tumors are classified as CIMP-high (CIMP-H) or CIMP-low (CIMP-L), based on 
the number of methylated markers (Al-Sohaily et al., 2012; Colussi et al., 2013). CIMP-H 
CRCs often contain BRAF gene mutations, which are associated with increased cell 
growth and progression of carcinogenesis. BRAF V600E (Val600Glu) mutation is present 
in 80 to 90% of CRC cases with sessile serrated adenomas (SSA) but is mostly absent in 
conventional adenomas. Additionally, BRAF mutations are present in early hyperplastic 
polyps (the serrated precursors) or in late dysplastic serrated adenomas that frequently 
have CIMP-H and MSI-H features, which leads to the hypothesis that the serrated 
pathway is involved in the sporadic CIMP CRCs development (Worthley et al., 2007; 
Leggett & Whitehall, 2010; Colussi et al., 2013).  
Clinically, CIMP-H tumors have a particularly poor prognosis and are usually located in 
the proximal site of the colon, similar to MSI tumors (Worthley et al., 2007; Bogaert & 
Prenen, 2014). On the other hand, CIMP-L tumors have a low level of DNA methylation 
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and, instead of the BRAF mutations observed in CIMP-H tumors, they are usually 
associated with KRAS and MGMT mutations (Worthley et al., 2007; Colussi et al., 2013; 
Bogaert & Prenen, 2014). 
 
 
 
 
 
 
 
 
 
 
KRAS and NRAS mutational status and its importance in 
CRC treatment 
 The disclosure that patients with activating KRAS gene mutations do no benefit from 
anti-EGFR therapy (cetuximab or panitumumab) surfaced after a series of initial 
retrospective analyses. This made KRAS mutations emerge as the only negative 
biomarker predictor of response to this therapy. To better understand how KRAS 
activating mutations influence anti-EGFR therapy’s efficacy, it is necessary to understand 
the link between EGFR and RAS in CRC. 
 
EGFR signaling pathways in CRC 
EGFR, also known as HER1/ERBB1, belongs to the ErbB family of receptor TKs, 
which comprises three other members: HER2 (ERBB2/neu), HER3 (ERBB3) and HER4 
(ERBB4). All proteins of this family are anchored in the cytoplasmic membrane and share 
a similar structure composed by an extracellular ligand-binding domain, a single 
hydrophobic transmembrane domain and a cytoplasmic TK-containing domain (Spano et 
al., 2005; Normanno et al., 2006; Scaltriti & Baselga, 2006). In normal cells, EGFR 
signaling pathway is activated in a ligand-dependent manner. ErbB family members can 
be activated by several known ligands, such as epidermal growth factor (EGF), 
transforming growth factor α (TGF-α), amphiregulin and epiregulin, that bind specifically to 
EGFR (Hynes & MacDonald, 2009).  
Figure 6. Genetic instability pathways and their overlapping relationships 
[adapted from (Markowitz & Bertagnolli, 2009)].    
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EGFR activation by ligand binding induces the dimerization of the receptor with 
formation of homo- and heterodimers that leads to autophosphorylation of specific 
tyrosine residues within the cytoplasmic tail of the receptors, initiating intracellular 
signaling via several pathways, namely RAS/RAF/ERK, PI3K/AKT, JAK/STAT and PLCϒ 
(Figure 7) (Normanno et al., 2006; Scaltriti & Baselga, 2006). These signal transduction 
cascades are responsible for diverse cellular responses, such as proliferation, migration, 
differentiation and apoptosis. Constitutional activation of these pathways can be achieved 
by receptor overexpression or activating mutations, which are common in several 
malignancies, including CRC (Normanno et al., 2006; Roberts & Der, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The RAS/RAF/ERK pathway 
The RAS/RAF/ERK pathway is one of the most deregulated signaling pathways in 
human cancer. In this pathway, RAS activation leads to a sequential activation of three 
MAPKs (RAF, MEK and ERK), which in turn generate signals that promote regulation of 
several cellular responses that establish cell proliferation, survival and differentiation 
(Dhillon et al., 2007; Roberts & Der, 2007). 
 
Figure 7. EGFR signaling pathways [adapted from (Scaltriti & Baselga, 2006)]. 
 MUTATIONAL ANALYSIS OF KRAS AND NRAS IN METASTATIC COLORECTAL CANCER 
 
 18 
RAS proteins – KRAS, HRAS and NRAS – are important components of a large family 
of small GTP-binding proteins. These three members of the RAS family are composed of 
a C-terminal and N-terminal regions, both important for RAS proteins functions. The C-
terminal region contains a CAAX motif, which is the target of post-translational 
modifications that allow the recruitment of the proteins to the inner face of the plasma 
membrane, essential for their normal function (Downward, 2003; Karnoub & Weinberg, 
2008). On the other hand, the N-terminal region is an important regulator of the protein 
GDP-bound and GTP-bound states. The structural differences between these states 
reside in two regions of the N-terminal, the switch I and switch II regions. Binding of the 
GTP molecule alters the conformation of both switch regions and allows the RAS protein 
to remain in an active state. Upon the release of the GTP’s extra phosphate group, the 
switch regions modify their conformation and return to the inactive state (Karnoub & 
Weinberg, 2008; Santarpia et al., 2012). This GDP/GTP cyclic process is catalyzed by 
guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs), with 
the former facilitating the exchange from GDP to GTP and the latter promoting the 
hydrolysis of GTP to GDP (Figure 8). The balance between these proteins is important to 
determine the activation of the RAS protein and its downstream target pathways 
(Downward, 2003; Santarpia et al., 2012). 
 
 
 
 
 
 
 
 
 
In normal cells, RAS becomes activated upon extracellular stimuli, which activate 
receptor TKs such as EGFR.  The autophosphorylated receptor then binds to the SH2 
domain of the adaptor protein growth-factor-receptor-bound protein 2 (GRB2). Since the 
SOS (GEF) is connected to the same adaptor protein in the SH3 domain, the binding of 
the receptor to the GRB2 brings SOS in close proximity to the RAS protein, leading to its 
activation (Downward, 2003; Roberts & Der, 2007). Activated RAS interacts with three 
closely related RAF kinases (c-RAF1, BRAF and ARAF), mobilizing them to the plasma 
membrane, where they become activated. Then, Raf kinases phosphorylate MEK1 and 
MEK2 (MAPKKs), which in turns triggers the phosphorylation and activation of MAPKs 
(ERK1 and ERK2) (Figure 9).  Once activated, ERK1 and ERK2 are translocated to the 
Figure 8. Upstream signaling of RAS and its control by the GDP-
GTP cycle [adapted from (Downward, 2003)]. 
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nucleus, where they regulate the activity of various transcription factors (Downward, 2003; 
Roberts & Der, 2007; Santarpia et al., 2012).  
Since this is a complex signaling pathway that ensures essential cellular responses, its  
deregulation is an important key factor to cancer progression. Several mechanisms, such 
as KRAS and BRAF activating mutations or EGFR overexpression, contribute to an 
improper activation of the pathway and have been described in several tumor types, 
including CRC. Furthermore, it was also identified that Erk activation can induce 
upregulation of EGFR ligands, which promotes an autocrine growth loop crucial for tumor 
growth (Roberts & Der, 2007; Santarpia et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
Predictive biomarkers of anti-EGFR therapy response 
As stated before, several retrospective studies of KRAS mutational status in tumors 
from patients treated with anti-EGFR therapy found that activating mutations in KRAS 
codons 12 and 13 were associated with a lack of response to these therapies (Table 3a 
and 3b). Mutations in these particular codons in KRAS exon 2, present in nearly 40% of all 
mCRC patients, cause constitutive activation of the RAS/ /ERK pathway, despite EGFR 
inhibition. Thus, screening for these mutations is recommended before therapy, since only 
patients with KRAS wild-type mCRC will benefit from it. However, among those patients 
with KRAS exon 2 wild-type tumors, only 40-60% responds to anti-EGFR therapy (De 
Roock et al., 2008; Lievre et al., 2008). This suggests that other activating mutations 
along this pathway may also confer resistance to anti-EGFR therapies. So, there is a 
Figure 9. Oncogenic activation of the RAS/RAF/ERK signaling pathway [adapted from 
(Roberts & Der, 2007)]. 
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great need to identify alternative predictive biomarkers that will distinguish patients who 
are most likely to benefit from this type of therapy.  
The first attempts to identify such biomarkers led to the discovery that positive EGFR 
overexpression (determined by immunohistochemistry) has no correlation with treatment 
response (Chung et al., 2005) and that the association between increased EGFR gene 
copy number (detected by FISH) and treatment response remains uncertain/controversial 
(Moroni et al., 2005; Laurent-Puig et al., 2009). These findings make it difficult to establish 
EGFR alterations as predictive biomarkers for treatment response. However, several 
studies have been focusing in the analysis of other targets, such as other EGFR 
downstream effectors (BRAF, NRAS, and PIK3CA), as well as less frequent KRAS 
mutations (De Roock et al., 2010; Guedes et al., 2013). 
 Recent analyses of tumors from patients enrolled in clinical trials demonstrated that 
other KRAS (codons 59/61 – exon 3; codons 117/146 – exon 4) or NRAS (codons 12/13 – 
exon 2; codons 59/61 – exon 3; codons 117/146 – exon 4) mutations lead to increased 
levels of RAS-GTP. These recent studies also reported that most patients harboring these 
rarer mutations did not achieve an objective response with anti-EGFR therapy (Douillard 
et al., 2013; Seymour et al., 2013). Given this, recent guidelines for anti-EGFR CRC 
treatment recommend the evaluation of the mutational status of the three exons of both 
genes before treatment initiation with anti-EGFR therapy.  
 
 
 
Table 3. Design characteristics used in A) meta-analysis and B) the change in median progression-free 
survival in KRAS wild-type and mutant groups of each study [adapted from (Adelstein et al., 2011)].  
A 
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1
(Amado et al., 2008) 
2
(Karapetis et al., 2008) 
3
(Van Cutsem et al., 2009) 
4
(Van Cutsem, Lang, et al., 2010) 
5
(Peeters et al., 
2010)
 6
(Bokemeyer et al., 2009)
 7
(Bokemeyer et al., 2011)
 8
(Maughan et al., 2010) 
9
(Douillard et al., 2010)
 10
(Tveit et al., 
2010)
 11
(Hecht et al., 2009) 
12
(Tol et al., 2009) 
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II. AIMS OF THE STUDY 
 
 
 
The aim of this study was to establish the type and frequency of other KRAS and 
NRAS mutations in a large consecutive series of mCRC wild-type for KRAS exon 2 
(codons 12/13) in order to contribute for the characterization of Portuguese patients. 
 
The specific aims were: 
I) To analyze the mutational status in mCRC by high resolution melting and 
automated Sanger sequencing of the following genes and exons: 
a. KRAS exons 3 (codons 59/61) and 4 (codons 117/146); 
b. NRAS exons 2 (codons 12/13), 3 (codons 59/61) and 4 (codons 117/146); 
 
II) To determine the frequency and type of mutations in each of the above genes 
and exons in Portuguese mCRC patients; 
 
III) To establish associations between the tumor genetic alterations and 
clinicopathological features in mCRC patients; 
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III. MATERIALS AND METHODS 
 
 
 
Samples 
A consecutive series of formalin-fixed paraffin embedded tumor samples from 400 
patients eligible for anti-EGFR therapy were selected to be retrospectively analyzed. All 
these samples belong to patients referred to the Genetics Department of IPO-Porto 
between August 2008 and December 2012 for KRAS exon 2 (codons 12/13) mutation 
analysis. Of the 400 samples analyzed, 243 were considered wild-type by PCR or high 
resolution melting (HRM), followed SNaPshot and/or automated sequencing. In our study, 
those 243 KRAS exon 2 wild-type samples were analyzed for mutations in KRAS (codons 
59/61 – exon 3; codons 117/146 – exon 4) or NRAS (codons 12/13 – exon 2; codons 
59/61 – exon 3; codons 117/146 – exon 4). Of these 243 samples, 2 were excluded due 
to lack/poor quality DNA. 80 samples had previously been analyzed, for KRAS exon 3 
(codons 59/61) and KRAS exon 4 (codon 146), by our group in another study (Guedes et 
al., 2013). Of the final 241 cases analyzed, histopathology reports were available for 215 
cases (66 women and 149 men). Median age of diagnosis was 58 years old and tumor 
localization was as follows: 23 ascending colon, 14 descending colon, 1 transverse colon, 
62 sigmoid colon and 115 rectum tumors. This study was approved by the institutional 
review board of the Portuguese Oncology Institute - Porto. 
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DNA extraction from formalin-fixed paraffin-embedded tissue 
Whenever possible, tumor areas containing at least 50% of tumor cells were delimited, by 
a pathologist, in the hematoxylin and eosin (H&E) stained slides of each sample. The 
corresponding unstained slides were immersed in xylene [SIGMA] and twice in ethanol 100% 
[Merck] for 5 minutes each. Tumor areas, which were previously delimited by comparison 
with the correspondent H&E stained slides, were macrodissected and transferred to a 
microcentrifuge tube. DNA was isolated using the QIAamp® DNA FFPE Tissue Kit [QIAGEN], 
following manufacturer’s instructions. Finally, DNA was quantified by spectrophotometry 
with NanoDrop ND-1000® [NanoDrop Technologies]. 
 
Mutational status analysis  
All samples were initially screened by HRM for mutations in KRAS (NM_004985) exons 
3 and 4 and NRAS (NM_002524.4) exons 2, 3 and 4, followed by automated DNA Sanger 
sequencing of one strand (forward or reverse), in order to evaluate the presence/absence 
of DNA alterations. A second HRM was performed in all positive samples of the initial 
analysis, followed by automated DNA Sanger sequencing of both strands. 
 
High Resolution Melting  
PCR amplification and HRM analysis were both performed on a LightCycler-480 II 
Real-Time System [Roche Diagnostics]. The PCR reaction mixture added to each well, of a 96 
well plate, was composed of a pair of primers (forward and reverse), DNA of each sample 
and PCR reagents (Table 4). To prevent contamination and/or evaporation, 15µL of 
mineral oil were added to each well. The plate was then sealed with sealing film and 
centrifuged at 2000rpm for 2 minutes. 
 
                                   Table 4. Components of the PCR reaction mixture. 
PCR reaction mixture components 
2,5x LightScanner® Master Mix [Idaho] 4.0µL 
Forward primer [frilabo] 350nM 
Reverse primer [frilabo] 350nM 
DNA 20-100ng 
Reagent grade water [Idaho] 4.9µL 
Total reaction volume 10µL 
 
The primer pairs used in this study for NRAS exons 2, 3 and 4 and KRAS 3 and 4 were 
all designed with primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast) 
and are available upon request to the Department of Genetics of IPO-Porto. 
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PCR amplification and HRM conditions were the same for all NRAS exons and for 
KRAS exon 3. KRAS exon 4 conditions differed from those applied to the exons 
mentioned above. However, all exons were subjected to an initial denaturation, followed 
by 35-40 cycles of amplification. After that, one cycle of heteroduplex and one of melting 
were done before the plate was cooled to 40ºC. The detailed conditions are described, 
separately, below: 
 
I. For all NRAS exons and for KRAS exon 3: An initial denaturation at 95ºC for 15 
minutes was followed by 35 cycles of 10 seconds at 95ºC, 20 seconds at 69ºC and 
30 seconds at 72ºC. After that, one heteroduplex cycle was done at 97ºC for 1 
minute and 40ºC for 2 minutes, followed by one melting cycle from 70ºC to 95ºC 
with 25acquisitions/ºC. The plate was finally cooled to 40ºC for 1 minute with a 
ramp rate of 2.2ºC/second. 
II. For KRAS exon 4: Initial denaturation was done at 95ºC for 10 minutes and 
followed by 35 cycles of 20 seconds at 95ºC, 20 seconds at 65ºC and 20 seconds 
at 72ºC, with a final extension of 10 minutes at 72ºC. One heteroduplex and one 
melting cycle were done after that, with the samples being denatured with an initial 
hold of 5 minutes at 95ºC and 1 minute at 40ºC (heteroduplex cycle), followed by a 
melting profile from 70ºC to 90ºC with 25acquisitions/ºC (melting cycle). The plate 
was cooled to 40ºC in the same conditions as described before for all NRAS exons 
and KRAS exon 3. 
 
Amplification and melting curves were obtained and analyzed using the LightCycler® 
480 Gene Scanning software v1.5 [Roche diagnostics]. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 10. High resolution melting analysis of KRAS exon 3. A) 
Normalized and B) difference graph, with wild-type (blue) and mutated 
(green and red) samples. 
A 
B 
 MUTATIONAL ANALYSIS OF KRAS AND NRAS IN METASTATIC COLORECTAL CANCER 
 
 32 
DNA Sequencing 
Before sequencing, all PCR amplification products were purified to remove excess of 
primers, salts, enzymes and dNTPs from the previous reaction. For that purpose, Illustra 
GFX PCR DNA and Gel Bad Purification Kit [GE Healthcare Life Sciences] and NZYGelpure Kit 
[nzytech] were used, according to the manufacturer’s protocol. 
After that, 1µL of each sample product was used for the sequencing reaction, which 
also contained 0.5µL of Big Dye® Terminator v1.1 cycle sequencing Ready Reaction Mix 
[Applied Biosystems], 3.4µL of Big Dye® Terminator v1.1, v1.3 5x sequencing buffer [Applied 
Biosystems], 350nM of one of the primers (forward or reverse) and 4.78µL of bidestilled sterile 
water [B. Braun], to a total volume of 10µL. Samples were then subjected to an initial 
denaturation at 95ºC for 4 minutes, followed by 35 cycles of 95ºC for 10 seconds, 50ºC for 
10 seconds and 60ºC for 2 minutes, with a final extension of 60ºC for 10 minutes. 
PCR sequencing products were purified using Illustra Sephadex® G-50 fine [GE Healthcare 
Life Sciences] and added to 12µL of Hi-Di
TM Formamide [Applied Biosystems]. The products were then 
run in either an ABI PRISMTM 310 Genetic Analyzer [Applied Biosystems] or a 3500 Genetic 
Analyzer [Applied Biosystems]. Electropherograms of each sample were analyzed with the 
Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were read at least twice, 
reviewed manually and with the Mutation Surveyor Software v4.0.8. 
 
 
Statistical analysis 
Statistical analysis was performed using either Qui-square or Fisher’s exact tests to 
assess statistical differences between the variants. Associations were considered 
statistically significant when P≤0.05. Statistical analysis was performed with the SPSS 
Statistics software package v.22.0. 
A 
B 
Figure 11. Electropherogram of KRAS exon 3 sequence, with A) a wild-type and B) a mutated sample. 
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IV. RESULTS 
 
 
 
DNA from a total of 241 KRAS exon 2 wild-type mCRC samples were screened in 
parallel for mutations in exons 3 and 4 of KRAS and exons 2, 3 and 4 of NRAS by HRM 
and automated sequencing. Automated sequencing of the HRM products confirmed the 
presence of 46 mutations (19.1%) in KRAS exons 3/4 or NRAS exons 2/3/4, with the 
remaining 80.9% (195/241) being wild-type for all regions studied. All mutations were 
found in heterozygosity and as a single mutation. 
 
Table 5. Mutational status of the 241 mCRC samples analyzed. 
Samples 
Mutational Status Frequencies 
Mutant 46 
Wild-type 195 
Total 241 
 
Mutational Type and Distribution 
Overall, 12.4% (30/241) of the cases presented a mutation in KRAS and 6.6% (16/241) 
were NRAS mutated. The mutational distribution of the 46 positive cases was as follows: 
65.2% (30/46) in KRAS, with 28.3% (13/46) in KRAS exon 3 and 37.0% (17/46) in KRAS 
exon 4, and 34.8% (16/46) in NRAS, with 17.4% (8/46) in NRAS exon 2 and 17.4% (8/46) 
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in NRAS exon 3 (Figure 12). No mutations were found in exon 4 of NRAS. The individual 
mutations found in each gene are presented in Tables 6 and 7. Eleven different mutations 
were found in KRAS and seven different mutations were detected in NRAS. In all but two 
cases the mutations were missense, whereas the remaining two cases had an in frame 
duplication and an in frame deletion in KRAS exon 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. KRAS mutations identified after automated sequencing. 
KRAS  
Case Exon Mutation Nr. 
73 3 c.151_195dup p.Cys51_Ser65dup 1 
5 3 c.176_178del p.Asp59del 1 
216 3 c.175G>A p.Ala59Thr 1 
175 3 c.179G>A p.Gly60Asp 1 
68, 87, 138, 141, 192 3 c.182A>T p.Gln61Leu 5 
39, 84, 209 3 c.183A>C p.Gln61His 3 
224 3 c.183A>T p.Gln61His 1 
78, 93, 213 4 c.351A>T p.Lys117Asn 3 
165 4 c.351A>C p.Lys117Asn 1 
19, 30, 47, 49, 108, 119, 120, 
131, 173, 200, 235 
4 c.436G>A p.Ala146Thr 11 
149, 164 4 c.437C>T p.Ala146Val 2 
  Total 30 
Figure 12. Distribution (%) of the 46 mutations detected in all analyzed exons 
in mCRC samples. 
RESULTS  
 
 37 
B                                                                                         p.Gln61His 
Table 7. NRAS mutations identified after automated sequencing 
NRAS  
Case Exon Mutation Nr. 
31, 88 2 c.34G>T p.Gly12Cys 2 
40, 64, 118, 220, 228 2 c.35G>A p.Gly12Asp 5 
139 2 c.37G>C p.Gly13Arg 1 
13, 26, 227 3 c.181C>A p.Gln61Lys 3 
38, 111 3 c.182A>G p.Gln61Arg 2 
124 3 c.182A>T p.Gln61Leu 1 
4, 52 3 c.183A>T p.Gln61His 2 
  Total 16 
 
 
 
Novel Mutations 
Of the 11 different KRAS mutations and seven different NRAS mutations identified in 
this study, the mutation c.183A>T, p.Gln61His, is novel (Figure 13) and the remaining 17 
mutations have previously been reported in the COSMIC database (COSMIC) or in the 
literature. 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Figure 13. Electropherograms of the mutation found in NRAS exon 3 that was not previously 
described, with A) wild-type and B) mutant sample. 
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Clinicopathological Associations 
The establishment of associations between the tumor genetic alterations and 
clinicopathological features was possible in 215 out of 241 cases. 
Mutation frequencies in this subgroup are described below (Table 8/Figure 14). Qui-
square or Fisher’s exact tests (each one used when appropriate) were done to assess 
differences between KRAS and NRAS mutation distribution and the following variables: 
sex, age and stage at diagnosis, and primary tumor site. 
              
Table 8. Mutational status in the subgroup of cases with available clinical data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples 
Mutational Status Frequencies 
KRAS mutant 28 
NRAS mutant 12 
Wild-type 175 
Total 215 
Figure 14. Mutational status (%) in the subgroup of cases with available clinical data. 
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Table 9. Distribution of KRAS and NRAS 
mutations according to patient sex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No differences were found regarding KRAS or NRAS mutation distribution by patient 
gender: 12.1% in men vs. 15.2% in women (p=0.537) for KRAS and 4.7% in men vs. 
7.6% in women (p=0.520) for NRAS.  
 
 
 
 
Sex 
KRAS 
Total 
Wild-Type Mutant 
Men 131 18 149 
Women 56 10 66 
Total 187 28 215 
Sex 
NRAS 
Total 
Wild-Type Mutant 
Men 142 7 149 
Women 61 5 66 
Total 203 12 215 
NRAS 
KRAS p=0.537 
p=0.520 
Figure 15. Distribution of KRAS and NRAS mutations 
according to patient sex. 
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Table 10. Distribution of KRAS and NRAS 
mutations according to patient age at 
diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Age at diagnosis was divided into two groups (<58 and ≥58, with 58 being the average 
age at diagnosis) for statistical purposes. No statistically significant differences were found 
in KRAS (p=0.612) or NRAS (p=0.178) mutation distribution according to age at 
diagnosis.   
 
 
 
Age at 
diagnosis 
KRAS 
Total 
Wild-Type Mutant 
<58 83 11 94 
≥58 104 17 121 
Total 187 28 215 
Age at 
diagnosis 
NRAS 
Total 
Wild-Type Mutant 
<58 91 3 94 
≥58 112 9 121 
Total 203 12 215 
NRAS 
KRAS p=0.612 
p=0.178 
Figure 16. Distribution of KRAS and NRAS mutations 
according to patient age at diagnosis. 
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Table 11. Distribution of KRAS and NRAS 
mutations according to patient stage at 
diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
KRAS mutations were more frequent (p=0.001) in earlier stages of diagnosis than in 
later ones (25.0% vs. 8.4%). However, NRAS mutations do not follow the same tendency, 
since no statistical differences were found between the two groups of stages (6.7% vs. 5.2 
%; p=0.742). 
 
 
Stage at 
diagnosis 
KRAS 
Total 
Wild-Type Mutant 
I+II 45 15 60 
III+IV 142 13 155 
Total 187 28 215 
Stage at 
diagnosis 
NRAS 
Total 
Wild-Type Mutant 
I+II 56 4 60 
III+IV 148 8 155 
Total 203 12 215 
KRAS p=0.001 
NRAS p=0.742 
Figure 17. Distribution of KRAS and NRAS mutations 
according to patient stage at diagnosis. 
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Table 12. Distribution of KRAS and NRAS 
mutations according to primary tumor site. 
 
 
 
 
 
 
 
 
 
 
 
There were relatively few tumors in the ascending, transverse and descending colon. 
For the purpose of this statistical analysis, the first three were grouped together as colon 
tumors. However, no statistical differences were found regarding KRAS (p=0.411) or 
NRAS (p=0.585) mutation distribution by primary tumor site.   
 
Tumor site 
KRAS 
Total 
Wild-Type Mutant 
Colon 31 7 38 
Sigmoid 53 9 62 
Rectum 103 12 99 
Total 187 28 215 
Tumor site 
NRAS 
Total 
Wild-Type Mutant 
Colon 36 2 38 
Sigmoid 60 2 62 
Rectum 107 8 115 
Total 203 12 215 
NRAS p=0.585 
KRAS p=0.411 
Figure 18. Distribution of KRAS and NRAS mutations 
according to primary tumor site. 
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V. DISCUSSION 
 
 
 
Important progress has been made in recent years regarding treatment of CRC, with 
the introduction of new therapies that improve patient survival even after metastasis 
development. The administration of anti-EGFR to mCRC patients negative for KRAS exon 
2 (codons 12/13) mutations improved considerably the outcome of those patients. These 
mutations occur in about 40% of mCRC patients and were established as the first 
negative predictors of response to anti-EGFR therapy. However, only 40 to 60% of all 
patients KRAS exon 2 wild-type achieve an objective response to this therapy (De Roock 
et al., 2008; Lievre et al., 2008). Such findings suggest that alterations in other EGFR 
downstream effectors may also predict response and lead to a further improvement of 
patient selection. 
Over the years, several studies analyzed the effect of KRAS mutations in response to 
anti-EGFR therapy, with the majority including only the mutational analysis of KRAS exon 
2 (codons 12/13) (Amado et al., 2008; Douillard et al., 2010; Peeters et al., 2010). 
However, recent studies show that less frequent mutations in KRAS exons 3 and 4 and 
mutations in NRAS exons 2, 3 and 4 are also associated with resistance to anti-EGFR 
therapy in mCRC (De Roock et al., 2010; Douillard et al., 2013; Peeters et al., 2013; 
Ciardiello et al., 2014). In fact, it was reported that patients with activating RAS mutations 
do not benefit from this therapy and may in fact be harmed by its administration (Douillard 
et al., 2013; Ciardiello et al., 2014).  
 MUTATIONAL ANALYSIS OF KRAS AND NRAS IN METASTATIC COLORECTAL CANCER 
 
 46 
In a consecutive series of 241 mCRC samples wild-type for KRAS codons 12 and 13, 
we searched for mutations in the less frequently mutated KRAS mutational hotspots in 
exon 3 (codons 59/61) and 4 (codons 117/146) and in exon 2 (codons 12/13), 3 (codons 
59/61) and 4 (codons 117/146) of NRAS. These hotspots are located in the P-loop domain 
(exon 2), switch II (exon 3) and G4/G5 regions (exon 4) of the highly conserved G domain, 
which is a common structure among RAS proteins (Edkins et al., 2006; Schubbert et al., 
2007). Initially, all samples were screened by HRM for mutations in KRAS and NRAS. 
Subsequently, automated DNA sequencing was performed in all HRM products, in order 
to identify the alterations associated with each of the mutant cases. HRM was used as a 
screening mutation method, instead of a regular PCR, since this technique is a very 
accurate, fast and sensitive method that allows the detection of a small fraction of mutated 
alleles in tumor samples (~5%), through the evaluation of the different melting patterns 
obtained from wild-type sequences vs. heterozygote variants (Krypuy et al., 2006; Pinto et 
al., 2011). Furthermore, sequencing of HRM products increases sensibility in mutation 
detection from 85% to 98% (Pinto et al., 2011). All HRM products were sequenced due to 
the fact that we obtained different rates of amplification among our samples and because 
of the use of big amplicons, such as those of KRAS and NRAS exon 4, which might 
decrease the sensitivity of mutation detection through HRM (Krypuy et al., 2006; Do et al., 
2008).  
The frequency of RAS mutations in this series (46/241 – 19.1%) is similar to that 
reported in recent studies with KRAS exon 2 wild-type mCRC, which ranges from 
approximately 15 to 20% (Vaughn et al., 2011; Douillard et al., 2013; Negru et al., 2014; 
Sorich et al., 2014). The mutational distribution of the 46 mutations is the following: 12.4% 
(30/241) were found in KRAS, 5.4% (13/241) and 7.1% (17/241) in exons 3 and 4, 
respectively; and 6.6% (16/241) were found in NRAS, 3.3% (8/241) in exon 2 and 3.3% 
(8/241) in exon 3. Although this mutational distribution slightly differs from that reported by 
Negru and collaborators (1.9% and 3.8% for KRAS exons 3 [codons 59/61] and 4 [codons 
117/146], and 7.8% and 1.9% for NRAS exons 2 [codons 12/13] and 3 [codons 59/61], 
respectively), it is very similar to that reported by Sorich and collaborators in a recent 
systematic review and meta-analysis of nine randomized controlled trials compromising a 
total of 5948 patients (4.3% and 6.7% for KRAS exons 3 [codons 59/61] and 4 [codons 
117/146], and 3.8% and 4.8% for NRAS exons 2 [codons 12/13] and 3 [codons 59/61], 
respectively) (Negru et al., 2014; Sorich et al., 2014). We did not detect mutations in 
NRAS exon 4 (codons 117/146), which seems to be a rare event in CRC, as indicated by 
the reported frequency ranging from 0.2 to 1% (Douillard et al., 2013; Negru et al., 2014; 
Sorich et al., 2014). 
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Aberrant RAS function found in cancer cells is typically associated with mutations in 
codons 12, 13 or 61, since these codons, located in the P-loop (codons 12 and 13) and in 
the switch region II (codon 61), play an important role in the maintenance of the GTP-GDP 
transition state. Mutations in these sites impair GTP hydrolysis and lead to the oncogenic 
activation of the protein (Scheffzek et al., 1997; Schubbert et al., 2007; Prior et al., 2012). 
Furthermore, it was demonstrated that the substitution of the Gln61 residue by other 
amino acids abolished GAP-dependent GTPase activation, leading to a constitutive 
activation of the RAS protein. This indicates that this amino acid is essential for GAP 
connection specificity to RAS GTPases (Nur & Maruta, 1992). In the present series only 
the NRAS gene was analyzed for codons 12 and 13 and the eight mutations detected 
resulted in three amino acid substitutions: p.Gly12Cys, p.Gly12Asp and Gly13Arg. 
Although the most frequent Gly12 mutant in our series was the Gly12Asp (5/8; 62.5%), its 
oncogenic potential is smaller than that of Gly12Val or Gly12Arg mutants (Schubbert et 
al., 2007; Prior et al., 2012), which we did not find.  
Codon 61 was analyzed in both KRAS and NRAS genes and nine mutations were 
found in KRAS and eight in NRAS, representing four different amino acid substitutions: 
p.Gln61Lys, p.Gln61Arg, p.Gln61Leu and p.Gln61His. One third (2/6) of all p.Gln61His 
mutants were found in NRAS and, according to the literature and the COSMIC database, 
this alteration has not previously been reported in this gene in CRC. Although there are no 
data concerning its oncogenic proprieties, the fact that it is located in Gln61 might be an 
indicator of its role in RAS activation. Just as for Gly12, Gln61 mutants have various 
transformation efficiencies that vary from 10 to 1000-fold. One of the highest 
transformation efficiencies is seen with the p.Gln61Leu mutant (Buhrman et al., 2007), 
which is also the most frequent Gln61 mutant in our series (7/17; 41.2%). However, in an 
analysis made by Vaughn and collaborators, p.Gln61Leu was found in only 17.1% (6/35) 
of KRAS and NRAS codon 61 mutations (Vaughn et al., 2011). We also observed that, 
despite their high degree of homology, the frequency of mutations in these three hotspots 
differs between these two RAS proteins. In KRAS, mutations in codons 12 and 13 are 
generally more frequent than in codon 61, however in our series mutations in NRAS were 
more frequent in codon 61 than in codons 12 and 13 (50% vs. 43.75% vs. 6.25%, 
respectively), which is in accordance with the literature (Fernandez-Medarde & Santos, 
2011; Prior et al., 2012). 
Due to a persistent bias in mutation screening over the years, the role of mutations in 
codons such as 59, 117 or 146 has been overlooked. Mutational analysis of these three 
codons was performed in our series, and mutations were found in all of them. Ala59 
mutants found in our series were all located in KRAS and included one point mutation 
(p.Ala59Thr), one in frame deletion (p.Ala59del) and one large in-frame duplication 
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(p.Cys51_Ser65dup). There are no sufficient data to understand how these alterations 
might influence RAS protein structure and function, but the fact that this codon is located 
in the switch region II, the same as codon 61, indicates that mutations in this codon might 
also influence the transition complex during GTP hydrolysis (Macaluso et al., 2002).  
On the other hand, mutations in codons 117 and 146, which are involved with guanine 
base interaction, are known to increase the GDP to GTP exchange rate without affecting 
the GTPase activity (Edkins et al., 2006). In fact, in vivo expression of both mutants 
resulted in elevated RAS-GTP expression compared with wild-type RAS, although lower 
than the one observed with KRAS codons 12 and 13 alleles (Janakiraman et al., 2010). In 
our series, mutations in these codons were also found only in KRAS, with four mutations 
in codon 117 and thirteen in codon 146 (23.5% and 76.5%, respectively). These 
mutations originated three different mutants, Lys117Asn, Ala146Val and Ala146Thr, with 
the latter being the most frequent mutant out of the three (11/17; 64.7%), something that 
is consistent with the findings in other publications (Janakiraman et al., 2010; Vaughn et 
al., 2011).  
Besides those mentioned above, we found one more mutation in KRAS exon 3, 
previously described by Molinari and collaborators (Molinari et al., 2011). This mutation, 
p.Gly60Asp, has no functional studies that can confirm its role as an activating mutation. 
However, this residue is a conserved amino acid in the superfamily of GTPases and is 
known to interact with ϒ-phosphate of GTP, which is consistent with the hypothesis that a 
mutation in this codon might be oncogenic (Bourne et al., 1991; Guedes et al., 2013).  
It is also important to mention the mutually exclusive distribution of mutations among 
KRAS and NRAS exons obtained in our series, since we only found single mutations in 
our pool of cases. This information suggests that alterations in these genes confer 
overlapping downstream effects due to functional redundancy, which is consistent with 
findings across the literature (De Roock et al., 2010; Janakiraman et al., 2010; Douillard et 
al., 2013). 
In the 215 cases with available clinical data, we tested for association between RAS 
mutations and clinicopathological features, such as gender, age and stage at diagnosis, 
and primary tumor site. Interestingly, an association was found between KRAS mutations 
(p=0.001) and earlier tumor stages at diagnosis, an association that was previously 
described (Fernandez-Medarde & Santos, 2011). No other statistically significant 
associations were found, but this might be due to the relatively small sample size and 
these findings should therefore be confirmed in larger series.  
Although it had been already suggested in the past (De Roock et al., 2010), the 
importance of RAS mutations, besides those in codons 12 and 13 of KRAS, as predictors 
of resistance to anti-EGFR has only recently been established. Douillard and collaborators 
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published recently the results of the PRIME trial, which assessed the efficacy and safety 
of adding panitumumab to FOLFOX4 in RAS mutated patients (Douillard et al., 2013). Of 
the 1183 patients who underwent randomization, 108 patients (17%; 108/620) without 
KRAS mutations in exon 2 had mutations in other RAS exons. In this subgroup of 
patients, the analysis showed that PFS and overall survival (OS) observed were shorter in 
the panitumumab-FOLFOX4 group than in the FOLFOX4-alone group (7.3 vs. 8.0 months, 
p=0.33; 17.1 vs. 18.3 months, p=0.31). Although the difference was not significant, these 
outcomes were consistent with those found for the subgroup of patients with KRAS 
mutations in exon 2. Moreover, patients without RAS mutations in the panitumumab-
FOLFOX4 group were associated with a significant improvement in progression free 
survival (10.1 vs. 7.9 moths, p=0.004) and overall survival (26.0 vs. 20.2, p=0.04), when 
compared with FOLFOX-alone.  
Similar results, concerning the addition of cetuximab to FOLFIRI in the treatment of 
mCRC patients, were reported by Ciardiello and collaborators in the latest results from the 
CRYSTAL trial (Ciardiello et al., 2014). 1198 randomized and treated patients were 
evaluated in this trial, and 14.7% (63/430) of those considered wild-type for KRAS codons 
12 and 13 tumors had other RAS mutations. The differences reported for PFS and OS in 
this subgroup, between the cetuximab-FOLFIRI and the FOLFIRI-alone groups, were not 
statistically significant (7.2 vs. 6.9 months, p=0.56; 18.2 vs. 20.7 months, p=0.50). 
However, when compared with the RAS wild-type subgroup results (11.4 vs. 8.4 months, 
p=0.0002; 28.4 vs. 20.2 months, p=0.0024) it is possible to conclude that the addition of 
cetuximab to FOLFIRI has no benefit for patients with RAS mutations. All these findings 
suggest that RAS activating mutations, in addition to KRAS exon 2 mutations, predict lack 
of response in patients who received anti-EGFR therapy (cetuximab or panitumumab). 
Due to the absence of information, at the time of writing, on the outcome of the RAS 
mutated patients treated with cetuximab/panitumumab, we could not evaluate the role of 
RAS mutations, as predictive biomarkers of treatment response, in this series of patients. 
However, considering the results obtained in our mutational analysis of 241 cases and the 
findings by Douillard and collaborators (Douillard et al., 2013) and Ciardiello and 
collaborators (Ciardiello et al., 2014), we can expect that about one-fifth of patients 
considered wild-type for KRAS exon 2 are unlikely to benefit from anti-EGFR therapy due 
to the presence of other RAS mutations. 
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VI. CONCLUSIONS 
 
 
 
Taking into account the results obtained in this study, we can conclude that: 
 
I) HRM followed by automated Sanger sequencing of KRAS exons 3 and 4 and 
NRAS exons 2, 3 and 4 allows the detection of other RAS mutations in about 
one-fifth of 241 Portuguese mCRC patients wild-type for KRAS exon 2; 
 
II) The 46 additional RAS mutations found are mutually exclusive and have the 
following distribution: 
a. 5.4% in KRAS exon 3; 
b. 7.1% in KRAS exon 4; 
c. 3.3% in NRAS exon 2; 
d. 3.3% in NRAS exon 3; 
 
III) Eleven and seven different mutations were found in KRAS and NRAS, 
respectively, with a novel NRAS exon 3 mutation being found in two cases; 
 
IV) In this setting, a statistically significant association was found between KRAS 
exon 3/4 mutations and early tumor stage at diagnosis. 
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VII. FUTURE PERSPECTIVES 
 
 
 
The results obtained in this work show that the overall frequency and type of mutations 
found in KRAS (exons 3 and 4) and NRAS (exons 2, 3 and 4) in Portuguese mCRC 
patients are in accordance with those previously reported in literature in other populations 
and may help to distinguish patients who are most likely to benefit from anti-EGFR 
therapy. However, further studies are still necessary to determine the full therapeutic 
implications of the mutations found in our series, including in vitro and in vivo tests to 
evaluate the oncogenic potential of the novel NRAS mutation here described. 
It will be important to analyze all available clinical data of each mutated patient in order 
to identify those who were treated with cetuximab or panitumumab and to find out which 
were the therapy responses. The comparisons of these data with those of RAS wild-type 
patients treated with the same drugs will eventually allow us confirm their importance as 
negative predictors of response to anti-EGFR therapy. 
Finally, mutational analysis of other potential predictive biomarkers of response, such 
as BRAF and PIK3CA, might contribute to further improve patient selection for effective 
anti-EGFR therapy in the future. 
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